COLL Collegium Pharmaceutical, Inc.
USHealthcareAs of 2026-07-10 15:44
Why COLL matters now
Collegium Pharmaceutical, Inc. (COLL) is a US stock in Healthcare. The latest InvestLog snapshot shows $35.34 with -1.30% on the session and $1.15B in market capitalization; recent performance reads 1-month -0.24% and YTD -27.56%.
The latest financial table shown here is Q1 2026, with revenue of $193.5M, net income of $14.5M, and EPS of $0.40. Investors can compare that operating picture with valuation signals such as P/E 17.91 and FCF yield 30.3%.
The latest indexable market news headline is "Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $58.00; recent insider activity includes SANTINI GINO filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
17.91
PEG
—
P/B
3.44
P/S
1.37
EV/EBITDA
2.67
DCF Value
$650.01
FCF Yield
30.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.7%
Operating Margin
23.8%
Net Margin
9.4%
ROE
26.7%
ROA
4.5%
ROIC
10.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $193.5M | $14.5M | $0.40 |
| Q4 2025 | $205.4M | $17.0M | $0.46 |
| FY 2025 | $780.6M | $62.9M | $1.73 |
| Q3 2025 | $209.4M | $31.5M | $0.84 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$58.00
Target (Median)
$58.00
Target Range
$56.00 - $60.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.75
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.